SCHEMBL556729

SCHEMBL556729

NC(=O)c1ccn2ccnc2c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3C3 Q8NEB9 1/20 0.43
HSD11B1 P28845 2/20 0.42
NAMPT P43490 2/20 0.42
LCK P06239 1/20 0.38
SSTR4 P31391 1/20 0.38
MKNK1 Q9BUB5 1/20 0.37
MKNK2 Q9HBH9 1/20 0.37
LMNA P02545 1/20 0.36
KDM4B O94953 1/20 0.36
KDM5C P41229 1/20 0.36
KDM5B Q9UGL1 1/20 0.36
TBXAS1 P24557 1/20 0.36
PARP1 P09874 4/20 0.36
MAOB P27338 1/20 0.36
NTRK1 P04629 1/20 0.36
F7 P08709 1/20 0.35
F3 P13726 1/20 0.35
SARM1 Q6SZW1 1/20 0.35
SIRT2 Q8IXJ6 1/20 0.35
SIRT6 Q8N6T7 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL557414 0.84 KDM4C (0.44) PIK3C3HSD11B1NAMPTSSTR4KDM5C
SCHEMBL10138744 0.82 NTRK1 (0.48) PIK3C3HSD11B1NAMPTSSTR4MAOB
Hydrochloric Acid SCHEMBL23089217 0.82 KDM4C (0.43) PIK3C3HSD11B1NAMPTSSTR4KDM5C
SCHEMBL14144286 0.81 NAMPT (0.42) PIK3C3HSD11B1NAMPTSSTR4MAOB
SCHEMBL1427735 0.81 NAMPT (0.50) PIK3C3HSD11B1NAMPTSSTR4LMNA
SCHEMBL1793919 0.79 NAMPT (0.48) PIK3C3HSD11B1NAMPTSSTR4MAOB
SCHEMBL12618926 0.79 KDM1A (0.38) PIK3C3HSD11B1NAMPT
SCHEMBL28813916 0.79 CYP17A1 (0.49) PIK3C3NAMPTMKNK1MKNK2TBXAS1
SCHEMBL15176490 0.78 NAMPT (0.47) PIK3C3HSD11B1NAMPTSSTR4TBXAS1
SCHEMBL12664206 0.78 SSTR4 (0.43) PIK3C3HSD11B1NAMPTSSTR4MAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3728234-B1 RADIOLABELED COMPOUNDS HOFFMANN LA ROCHE (CH) 2025-05-14 EP claimed
EP-3983389-A1 COMPOUNDS FOR TREATING RESPIRATORY DISEASE TMEM16A LIMITED (GB) 2022-04-20 EP claimed
US-20150266822-A1 Amide Compounds, Compositions And Uses Thereof RENOVIS, INC. 2015-09-24 US claimed
US-20130216498-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2013-08-22 US claimed
EP-2516436-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS Almirall S.A. (ES) 2012-10-31 EP claimed
WO-2011076419-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS ALMIRALL, S.A. (ES) 2011-06-30 WO claimed
EP-2262766-A2 AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF Renovis, Inc. (US) 2010-12-22 EP claimed
WO-2009110985-A2 AMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF RENOVIS, INC. (US) 2009-09-11 WO claimed
WO-2025067457-A1 HETEROCYCLIC FUSED RING COMPOUND, AND COMPOSITION AND USE THEREOF 深圳市塔吉瑞生物医药有限公司 2025-04-03 WO disclosed
US-12240862-B2 Inhibitors of peptidylarginine deiminases GILEAD SCIENCES, INC. (US) 2025-03-04 US disclosed
CN-117105936-B Imidazo [1,2-a ] pyridine compound serving as FLT3 inhibitor, and preparation method and application thereof 遵义医科大学 2025-01-24 CN disclosed
CN-119095839-A Quinoline derivatives as modulators and related products of Mas-associated G protein receptor X2 伊赛恩特制药公司 2024-12-06 CN disclosed
CN-114466850-B [1,2,4] Triazolo [1,5-C ] quinazolin-5-amine 拜耳股份有限公司 2024-09-10 CN disclosed
CN-114728965-B Pyrido heterocyclic compounds, preparation method and application thereof 四川科伦博泰生物医药股份有限公司 2024-05-28 CN disclosed
WO-2009047522-A1 BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2009-04-16 WO disclosed
WO-2009047522-A1 BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2009-04-16 WO disclosed
WO-2009047506-A1 BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2009-04-16 WO disclosed
WO-2009047506-A1 BICYCLIC HETEROCYCLIC COMPOUNDS AS PROTEIN TYROSINE KINASE INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2009-04-16 WO disclosed
WO-2008078091-A1 BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2008-07-03 WO disclosed
WO-2008078091-A1 BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2008-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130216498-A1 IMIDAZOPYRIDINE DERIVATIVES AS JAK INHIBITORS JAK1, JAK2, JAK3 PIK3C3 107/4885HSD11B1 4473/4885NAMPT 1406/4885
US-20150266822-A1 Amide Compounds, Compositions And Uses Thereof IL1B, ADORA2B, AVPR1B PIK3C3 4883/4885HSD11B1 1419/4885NAMPT 3195/4885
US-12240862-B2 Inhibitors of peptidylarginine deiminases PADI4, PADI2, PADI1 PIK3C3 902/4885HSD11B1 2344/4885NAMPT 555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.